Cancer drug delivery最新文献_第8页

Administration of interferon at night may increase its therapeutic index. 夜间使用干扰素可提高其治疗指数。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.313

V Bocci

引用次数: 39

Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. 重组干扰素α A在猴子体内的血浆和脑脊液药代动力学:静脉、肌肉和脑室给药的比较

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.247

J M Collins, R Riccardi, P Trown, D O'Neill, D G Poplack

引用次数: 42

Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. 高剂量甲氨蝶呤治疗儿童恶性肿瘤的减少citrovorum因子挽救。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.77

K Sasaki, J Tanaka, T Murakami, H Matuoka, T Fujimoto, H Taguchi

引用次数: 10

Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. 白细胞干扰素诱导的对化疗和/或放疗-脉冲治疗方案有耐药性的人类转移性癌症肿瘤消退的临床结果。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.53

R Medenica, N Slack

{"title":"Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule.","authors":"R Medenica, N Slack","doi":"10.1089/cdd.1985.2.53","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.53","url":null,"abstract":"The efficacy of Human 6 IFN (HLIFN) given in a pulse fashion was determined in a phase II study. Ninety-one cancer patients were evaluated (9 myeloma, 12 breast, 14 prostate, 9 melanoma, 4 renal, 6 astrocytoma, 7 ovarian, 9 large bowel, 7 gastric, 14 head and neck). They all had advanced progressive cancer that was resistant to chemotherapy and/or radiotherapy. Patients were treated by intramuscular injection of 6 X 10(2) I.U./m2 for three consecutive days every four weeks. 84 patients were evaluable. Complete clinical response was obtained in 23 patients (4 myeloma, 2 breast, 5 prostate, 1 melanoma, 1 renal, 2 astrocytoma, 2 ovarian, 2 large bowel, 1 gastric, 3 head and neck). Partial responses were observed in 35 patients (3 myeloma, 7 breast, 6 prostate, 4 melanoma, 1 renal, 2 astrocytoma, 3 ovarian, 4 head and neck). Objective responses were related (P less than 0.01) to serum IFN level, with complete and partial responses (P less than 0.01) more commonly seen in those patients whose serum IFN levels at two hours were in the range of 1000 to 1650 I.U./ml. Side effects resulting from pulse IFN were acceptable for this group of patients and consisted of fever, transient chills, malaise and asthenia, and transient thrombocytopenia and leukocytopenia. The extent of fever was directly related (P less than 0.01) to response, and was most elevated in patients who achieved objective responses. IFN administered in a pulse fashion appears to be more effective than daily IFN and merits further evaluation.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 1","pages":"53-76"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15164894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 41

Protective effect of liposomal-amphotericin B against C. albicans infection in mice. 脂质体两性霉素B对小鼠白色念珠菌感染的保护作用。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.183

G Lopez-Berestein, T McQueen, K Mehta

引用次数: 24

Clinical Results of Leukocyte Interferon-Induced Tumor Regression-Pulse Therapy Schedule 白细胞干扰素诱导肿瘤消退-脉冲治疗方案的临床结果

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/CDD.1985.2.1

A. Freeman

引用次数: 0

Mitomycin C carrying microspheres as a novel method of drug delivery. 丝裂霉素C微球作为一种新的给药方法。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.173

S Fujimoto, M Miyazaki, F Endoh, O Takahashi, K Okui, K Sugibayashi, Y Morimoto

{"title":"Mitomycin C carrying microspheres as a novel method of drug delivery.","authors":"S Fujimoto, M Miyazaki, F Endoh, O Takahashi, K Okui, K Sugibayashi, Y Morimoto","doi":"10.1089/cdd.1985.2.173","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.173","url":null,"abstract":"Biodegradable albumin microspheres containing about 5% mitomycin C (MMC) were prepared in an average diameter of 45 +/- 8 microns by heat denaturation in oil at 120 degrees C and/or cross-linking with glutaraldehyde. These MMC microspheres released, in vitro, about 20% of the contained MMC for over 3 days, and they were intra-arterially infused into albino rabbits and Wistar rats, as a preclinical model of intra-arterial infusion treatment for patients with inoperable hepatic tumor. We infused these microspheres into the femoral artery of rabbits with a VX-2 tumor implanted into the flank of the hindleg. High levels of MMC were maintained for several hours in the tumor and the entrapped MMC microspheres were detected within arterioles in the VX-2 tumors. The growth of VX-2 tumor was inhibited considerably, compared to findings in the control rabbits given conventional MMC. In the next studies, MMC microspheres were infused into the rat hepatic artery, and the levels of MMC in the hepatic vein blood were maintained at much the same concentration for over 2 hours after the infusion, in marked contrast to rapid decreases in the conventional MMC. Histologic findings revealed that MMC micro-spheres were entrapped within the hepatic arterioles for over 2 weeks and released biologically active MMC into the neighboring tissues for prolonged periods of time.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 3","pages":"173-81"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.173","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15046801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Molecular missiles and drug delivery. 分子导弹和药物输送。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.171

S E Order

引用次数: 2

Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70. 32%葡聚糖70腹腔注射维持腹膜导管功能。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.291

C E Pfeifle, S B Howell, I S Abramson, M Markman

{"title":"Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70.","authors":"C E Pfeifle, S B Howell, I S Abramson, M Markman","doi":"10.1089/cdd.1985.2.291","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.291","url":null,"abstract":"Thirty-two percent dextran 70 was administered to 53 patients receiving intraperitoneal (i.p.) chemotherapy in an attempt to better maintain catheter function. One hundred milliliters of 32% dextran 70 was administered i.p. at the time of catheter placement and at the completion of each course of chemotherapy (every 3 to 4 weeks). Analysis of the functional survival of the dextran treated catheters and 20 historical controls was performed. The cumulative probabilities of catheters maintaining bi-directional function in the dextran treated and control groups were 0.75 and 0.50 respectively. This difference was statistically significant at p = 0.051 by two-tailed Wilcoxon analysis. The difference between survival of dextran treated and control catheters increased if patients who received intraperitoneal doxorubicin were factored out (p = 0.035 by two-tailed Wilcoxon analysis). Plasma and peritoneal dextran levels were measured on 9 courses in 8 patients. Dextran was detectable in the peritoneal cavity up to 7 days after administration. The \"apparent half-life\" of dextran 70 in the peritoneal cavity was 36 hours. Plasma dextran concentrations increased for 2 days following i.p. administration and then decreased with an apparent half-life of 36 hours. One patient experienced chills and another had an anaphylactoid reaction following administration of the dextran. This study suggests that i.p. administration of 32% dextran 70 may be an effective means of minimizing peritoneal catheter failures.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"291-303"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.291","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13562461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Comparison of cytotoxicity of single dose and infusion of alkylating agents. 烷基化剂单剂量与灌注细胞毒性比较。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.11

F Valeriote, T Vietti

引用次数: 0